Regulation & Compliance

A landmark report reveals a crisis: 91% of biopharma firms lack the data maturity for AI, undermining patient care and stalling innovation.

Apollo's new Go Stellar scooter packs 32 MPH speeds and self-healing tires, targeting a key urban niche. But can it navigate a complex regulatory landscape?

With a new sales director and a booming market, Source 1 Solutions is positioning itself for aggressive growth in the competitive global IT services landscape.

The power cooperative will discuss its 2025 financials as it navigates massive infrastructure projects and record energy demand from Georgia's growing economy.

A new partnership between equipifi and Velera empowers thousands of credit unions to offer BNPL directly, aiming to win back members from fintech rivals.

Cravath holds its crown for the 11th year, but Vault's 2026-2027 rankings reveal major shake-ups, new power players, and the growing voice of associates.

New research reveals a 'data trust' crisis is derailing enterprise AI. With 80% of initiatives failing, CISOs are caught between speed and security.

UniX AI's new wheeled robot Panther enters homes, pushing a 'deployment-first' strategy. But this leap raises critical questions about privacy and safety.

The Calgary fintech is now a direct Interac e-Transfer participant, signaling more competition for big banks and more innovation for Canadian consumers.

A new $3.5M investment aims to dismantle complex college applications, using direct admissions to create a simpler, more equitable path to higher education.

Bristol AI scaleup Narwhal Labs launches DeepBlue OS, an autonomous agent platform designed for regulated industries with a transparent, pay-for-use model.

A native probiotic developed in Thailand is shown to reduce harmful toxins in kidney disease patients, offering a new, locally-tailored supportive therapy.

Saudi Arabia's Jood Eskan platform blends Islamic principles with digital efficiency, raising billions to house thousands and setting a new global standard.

Hemispherian launches a landmark trial for GLIX1, a first-in-class therapy aiming to selectively destroy glioblastoma cells where others have failed.

As Hong Kong's ETF market booms, ETF365.com.hk launches to provide transparent data, comparisons, and reviews for the everyday retail investor.

As global tech leaders convene, Hong Kong aims to cement its role as a digital super-connector amid rising debates on AI governance and cross-border data.

A wound care gel recall by Blaine Labs reveals a history of contamination issues and prior FDA warnings, posing serious risks to vulnerable patients.

Lupin wins FDA approval for its generic dapagliflozin, a move set to slash costs for a blockbuster diabetes and heart drug and reshape patient care.

After three rejections, Outlook Therapeutics escalates its fight for US approval of a key wet AMD drug, already sold in Europe. Will the FDA bend?

The leading health system is deploying Midstream Health's AI agents to tackle operational costs and secure long-term financial sustainability.